OncoMatch/Triple-Negative Breast Cancer (TNBC)/BRCA2
Triple-Negative Breast Cancer (TNBC)BRCA2 Clinical Trials
2 recruiting trials·Updated daily from ClinicalTrials.gov
Germline BRCA2 pathogenic variants occur in a subset of TNBC and are targetable with PARP inhibitors, which exploit the DNA repair defect created by BRCA2 loss. Olaparib and talazoparib are FDA-approved for germline BRCA1/2-positive HER2-negative metastatic breast cancer. Active trials study neoadjuvant PARP inhibitor strategies, somatic BRCA2 alteration eligibility, and platinum-based combinations in BRCA2-mutant TNBC.
Top recruiting
Top recruiting BRCA2 Triple-Negative Breast Cancer (TNBC) trials
Ranked by phase and US site count.
See all trials matched to your profile →Other Triple-Negative Breast Cancer (TNBC) biomarkers
Browse other molecular targets with active Triple-Negative Breast Cancer (TNBC) trials.